What we do Avience Biomedicals Limited manufactures in vitro diagnostic products and medical devices, supplying pathology labs, hospitals, and research centers in India and abroad. |
Founded in 2,019 |
Market share Growing presence domestically and internationally with significant revenue growth and expanding export footprint. |
Problem solved Provides affordable, quality diagnostic kits and medical devices to support disease detection and healthcare infrastructure. |
Top clients or who we serve B2B and B2G clients including pathology labs, microbiology labs, hospitals, and research centers. |
Key management Dharam Deo Choudhary (Chairman cum Managing Director) with experienced directors and key managerial personnel since 2019. |
Our journey and innovations Started with essential diagnostic kits, expanded into serology products, biochemistry analyzers, reagents, and acquired DR Meditech Surgical & Diagnostics as a subsidiary. |
Where we operate India with growing international exports and B2B/B2G operations across healthcare institutions. |
Top products or what we offer Viral Transport Media, COVID-19 kits, HIV, Malaria, Dengue tests, serology products, biochemistry analyzers, reagents. |
Top brands Flagship diagnostic kits and medical devices with presence in major healthcare verticals, expanding product portfolio. |
Raw materials needed Chemical reagents, biological materials, diagnostic components essential for IVD and medical device manufacturing. |
Raw materials supplier Not specified; likely sourced from specialized medical and chemical suppliers adhering to quality standards. |
Recurring vs cyclical contribution Revenue mainly from recurring product sales and contracts serving healthcare institutions in B2B/B2G markets. |
Our industry position Rapid revenue growth, strong export expansion, poised for IPO to amplify market presence in diagnostics sector. |
Financial highlights FY25 revenue Rs 288.9 crore, net profit Rs 50.0 crore with 77.7% sales growth over FY24; expanding financial base. |
Geographical revenue split Major domestic sales complemented by Rs 52.4 crore in exports during FY25, reflecting strategic overseas growth. |
Order book - |
Whats driving growth Rising healthcare demand, government support, indigenous manufacturing incentives, advanced technology adoption in diagnostics. |
Our future plans Launching IPO in FY26, enhancing production capacity, expanding product range, and strengthening export markets. |
Our green promise - |
Our people and values Focused on employee development, diversity, and fostering a compliant and ethical workplace culture. |
Key challenges ahead Maintaining regulatory compliance, scaling production efficiently, and navigating competitive healthcare market dynamics. |
Interesting facts Rapid growth since 2019 founding, acquisition of subsidiary in 2023, and upcoming IPO to fuel expansion. |
Risks and strategy Risks include market competition and regulatory hurdles; mitigation via enhanced internal controls and innovation. |
